Welcome to LookChem.com Sign In|Join Free

CAS

  • or
2-(cholest-5-en-3-yloxy)ethanol is a chemical compound with the molecular formula C27H48O2. It is an alcohol derivative of cholesterol, characterized by the presence of a cholesteryl group attached to an ethoxy group. 2-(cholest-5-en-3-yloxy)ethanol is known for its amphiphilic nature, which allows it to interact with both hydrophilic and hydrophobic environments, making it a versatile molecule for various applications.

30788-35-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 2-[[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclope

    Cas No: 30788-35-3

  • USD $ 100.0-2000.0 / Gram

  • 100 Gram

  • 50 Kilogram/Month

  • SHANGHAI SYSTEAM BIOCHEM CO., LTD
  • Contact Supplier
  • 2-[[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclope

    Cas No: 30788-35-3

  • USD $ 18.0-20.0 / Kilogram

  • 1 Kilogram

  • 10000 Metric Ton/Year

  • EAST CHEMSOURCES LIMITED
  • Contact Supplier
  • 2-[[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclope

    Cas No: 30788-35-3

  • USD $ 1.5-1.5 / Metric Ton

  • 1 Metric Ton

  • 1000 Metric Ton/Day

  • KAISA GROUP INC
  • Contact Supplier
  • 30788-35-3 Structure
  • Basic information

    1. Product Name: 2-(cholest-5-en-3-yloxy)ethanol
    2. Synonyms: poly(1,2-ethanediyloxy), α-hydroxy-ω-[(3β)-cholest-5-en-3-yl]-; Poly(oxy-1,2-ethanediyl), α-(3β)-cholest-5-en-3-yl-ω-hydroxy-; α-Hydroxy-ω-[(3β)-cholest-5-en-3-yl]poly(ethyleneoxy); 2-[(3β)-cholest-5-en-3-yloxy]ethanol
    3. CAS NO:30788-35-3
    4. Molecular Formula: C29H50O2
    5. Molecular Weight: 430.7061
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 30788-35-3.mol
    9. Article Data: 24
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 524.9°C at 760 mmHg
    3. Flash Point: 210.5°C
    4. Appearance: N/A
    5. Density: 1g/cm3
    6. Vapor Pressure: 3.28E-13mmHg at 25°C
    7. Refractive Index: 1.521
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. CAS DataBase Reference: 2-(cholest-5-en-3-yloxy)ethanol(CAS DataBase Reference)
    11. NIST Chemistry Reference: 2-(cholest-5-en-3-yloxy)ethanol(30788-35-3)
    12. EPA Substance Registry System: 2-(cholest-5-en-3-yloxy)ethanol(30788-35-3)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 30788-35-3(Hazardous Substances Data)

30788-35-3 Usage

Uses

Used in Pharmaceutical and Biotechnological Research:
2-(cholest-5-en-3-yloxy)ethanol is utilized as a research tool in pharmaceutical and biotechnological studies, particularly focusing on lipid metabolism and the role of cholesterol in biological processes. Its unique structure enables it to serve as a model compound for understanding cholesterol's interactions with other biomolecules and its impact on cellular functions.
Used in Drug Development and Therapeutic Interventions:
In the pharmaceutical industry, 2-(cholest-5-en-3-yloxy)ethanol is used as a potential candidate for drug development and therapeutic interventions targeting cholesterol-related disorders. Its ability to modulate cholesterol levels and influence lipid metabolism makes it a promising agent for the treatment of conditions such as atherosclerosis, hypercholesterolemia, and other lipid metabolism disorders.
Used in the Production of Lipid-Based Drug Delivery Systems:
2-(cholest-5-en-3-yloxy)ethanol is employed as a key component in the development of lipid-based drug delivery systems. Its amphiphilic nature allows it to form stable structures with cell membranes, facilitating the transport of therapeutic agents across biological barriers. This property makes it suitable for the design of targeted drug delivery systems, enhancing the bioavailability and efficacy of various drugs.
Used in Nanoformulations:
In the field of nanotechnology, 2-(cholest-5-en-3-yloxy)ethanol is used in the formulation of nanoscale drug delivery systems. Its ability to interact with cell membranes and form stable nanostructures enables the encapsulation and controlled release of therapeutic agents, improving their pharmacokinetics and therapeutic potential.
Additional research is necessary to fully explore the potential uses and implications of 2-(cholest-5-en-3-yloxy)ethanol in various fields, including its role in drug development, therapeutic interventions, and nanoformulations.

Check Digit Verification of cas no

The CAS Registry Mumber 30788-35-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,0,7,8 and 8 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 30788-35:
(7*3)+(6*0)+(5*7)+(4*8)+(3*8)+(2*3)+(1*5)=123
123 % 10 = 3
So 30788-35-3 is a valid CAS Registry Number.

30788-35-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-[[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]ethanol

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:30788-35-3 SDS

30788-35-3Relevant articles and documents

Syntheses of deuterium-labelled cholesteryl neoglycolipids

Lafont, Dominique,Boullanger, Paul,Gambetta, Antoine

, p. 88 - 95 (2012)

Four deuterium-labelled neoglycolipids derived from cholesterol were synthesized for embedment into liposomes. Deuterium atoms were either incorporated by CH2 replacement with a CD2 group in the triethylene glycol spacer arm between the cholesteryl residue and the sugar moiety (products 2-4) or incorporated directly on the acetamido function in the sugar head (compound 5). Copyright

Apoptosis inducing properties of 3-biotinylate-6-benzimidazole B-nor-cholesterol analogues

Zhu, Zhiling,Liu, Zhiping,Cui, Jianguo,Huang, Yanmin,Chen, Hualong,Wu, Yulan,Huang, Xiaotong,Gan, Chunfang

, (2021)

In this work, a series of Biotin-substituted B-nor-cholesteryl benzimidazole compounds were synthesized. The antiproliferative activities of these compounds were evaluated in vitro using a series of human cancer cell lines, including HeLa (cervical cancer), SKOV3 (ovarian cancer), T-47D (thymus gland cancer), MCF-7 (human breast cancer) and HEK293T (normal renal epithelial) cells. These compounds displayed distinct antiproliferative activities against the currently tested cancer cells. The apoptotic properties induced by compound 6d were further investigated. Our results showed that compound 6d could induce the apoptosis of SKOV3 cells, blocking the cell growth in S-phase. Western blotting analyses revealed that compound 6d can induce cell apoptosis via the mitochondria-dependent pathway.

LIPIDIC ANALOGS OF ANTI-CANCER STEM CELL AGENT

-

, (2020/09/19)

A group of specific sulfated flavonoid agents carrying cholesterol modification display promising in vivo anti-cancer activity through selective inhibition of cancer stem cells, and not of adult or hematopoietic stem cells. The compounds exhibit high potency, excellent oral bioavailability and a physiologically relevant therapeutic window.

Self-organization of cholesterol-side-chain liquid crystalline polymers by tailoring the main chain structure and flexible spacer length

Yang, Xiwen,Chen, Shaonan,Luo, Hang,Xu, Haoran,Chen, Sheng

, p. 5429 - 5440 (2019/04/04)

Three kinds of side-chain liquid crystalline polymers (SCLCPs), in which cholesteryl mesogens (Chol) were linked to polyacrylate (PCholAC-m), polymethacrylate (PCholMC-m), and poly(2-vinylbenzene-1,4-dioate) (PCholVA-m) backbones through methylene spacers of different lengths (m = 0, 2, 4, 6, 8, and 10), were successfully synthesized using free-radical polymerization. The phase behavior and structure of the polymers were investigated in detail using DSC, POM, and SAXS. The results indicated that the Chol-SCLCPs displayed interesting self-organization by varying the main-chain structure and spacer length. The polymers initially form a smectic A phase, except for PCholAC-0 without a liquid crystalline phase. Next, polymers PCholAC-m (m = 2, 4, 6) formed a two-layer smectic A phase in which the alkyl tail was overlapped (SmA2). Two-phase coexisting structures were observed in PCholAC-m (m = 8, 10), including a bilayer smectic A phase in which the alkyl tail was inserted into the mesogens (SmAd) and a single-layer smectic A phase in which the mesogens were overlapped (SmA1). Similar results were observed for PCholMC-m. Furthermore, PCholMC-0 possessed a stable bilayer SmA2 owing to the methyl steric effect of the main chain. PCholVA-m (m = 0, 2, 4) samples showed a well-defined smectic A phase in which the backbone was squeezed by the parallel side chains on both sides. PCholVA-6 and PCholVA-10 exhibited a SmAd phase. The two-phase coexisting structures were also found in PCholVA-8. Finally, the glass transition temperature of the polymers decreased with increasing flexible spacer length because the flexible spacer acted as an internal plasticizer in the system. However, changes in the polymer clearing points demonstrated the diversity resulting from the different smectic A phase structures.

3-biotin ether ester-B reduction-cholesteric benzimidazole compound and preparation method and application thereof

-

Paragraph 0043; 0048; 0052; 0057, (2019/01/16)

The invention discloses a 3-biotin ether ester-B reduction-cholesteric benzimidazole compound and a preparation method and application thereof. The 3-biotin ether ester-B reduction-cholesteric benzimidazole compound is characterized in that the chemical structure formula refers to the description, wherein n is an even number which is more than or equal to 2; R1 is H or CH3; R2 is H or OCH3. The 3-biotin ether ester-B reduction-cholesteric benzimidazole compound is obvious in effect on inhibiting cells of various tumor cell strains such as human uterine cervix cancer cell strains, ovarian carcinoma cell strains and human breast carcinoma cell lines; and meanwhile, the 3-biotin ether ester-B reduction-cholesteric benzimidazole compound is nontoxic to human renal epithelial cells and can be applicable to preparation of drugs for treating cancers.

Catalytic cyclometallation in steroid chemistry VI: Targeted synthesis of hybrid molecules based on steroids and tetradeca-5Z,9Z-diene-1,14-dicarboxylic acid and study of their antitumor activity

D'yakonov, Vladimir A.,Tuktarova, Regina A.,Dzhemileva, Lilya U.,Ishmukhametova, Svetlana R.,Yunusbaeva, Milyausha M.,Dzhemilev, Usein M.

, p. 6 - 13 (2018/06/18)

Hybrid molecules based on a number of steroids (cholesterol, pregnenolone, androsterone) and 1,14-tetradeca-5Z,9Z-dienedicarboxylic acid linked via mono- and diethylene glycol spacers were synthesized for the first time and studied for antitumor activity in vitro. The acid was prepared using catalytic cyclomagnesiation of oxygenated 1,2-dienes with Grignard reagent in the presence of Cp2TiCl2 as the key synthetic step. Using flow cytometry, the new molecules were shown for the first time to be efficient apoptosis inducers in the HeLa, Hek293, U937, Jurkat, and K562 cell cultures and to have dose-dependent effect on the S and G2 phases of the cell cycle.

FLUORESCENT ANTICANCER PLATINUM DRUGS

-

, (2018/11/21)

The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to fluorescent platinum based compounds. The disclosure further relates to synthesis of said fluorescent platinum based compounds, nanoparticles and compositions comprising said fluorescent platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by the fluorescence changes between aforesaid platinum based compounds and corresponding free ligands, nanoparticles and compositions.

CELLULAR SIGNALLING INHIBITORS, THEIR FORMULATIONS AND METHODS THEREOF

-

, (2017/09/05)

The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula (I), compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof.

Hybrid Lipids Inspired by Extremophiles and Eukaryotes Afford Serum-Stable Membranes with Low Leakage

Koyanagi, Takaoki,Cao, Kevin J.,Leriche, Geoffray,Onofrei, David,Holland, Gregory P.,Mayer, Michael,Sept, David,Yang, Jerry

supporting information, p. 6757 - 6762 (2017/05/29)

This paper presents a new hybrid lipid that fuses the ideas of molecular tethering of lipid tails used by archaea and the integration of cholesterol groups used by eukaryotes, thereby leveraging two strategies employed by nature to increase lipid packing

BIPOLAR TETRAETHER LIPIDS

-

Paragraph 0034; 0569; 0570, (2017/03/21)

Disclosed herein, inter alia, are compounds, compositions, and liposomes and methods of thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 30788-35-3